C4XD Inks Third Major Deal, This Time With AZ For Oral COPD Drug
Gets $2m Upfront
The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.
